6-11-17 PRESSEMEDDELELSE (Dansk)

Author Archives: WebMast

6-11-17 PRESSEMEDDELELSE (Dansk)

PRESSEMEDDELELSE Ny og lovende fosterdiagnostik er mere skånsom for gravide I fremtiden vil det måske blive muligt for gravide at undgå en moderkageprøve. En simpel blodprøve vil kunne give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. Mange gravide bliver bekymrede, hvis de får […]

read more

BREAKING – Simpel blodprøve kan erstatte moderkageprøve hos gravide

06. nov. 2017, 11:27 af Rizau Ny og lovende fosterdiagnostik er mere skånsom over for gravide, viser ny forskning. I fremtiden bliver det måske muligt for gravide at undgå en moderkageprøve. En simpel blodprøve kan give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. […]

read more

ARCEDI Biotech Readying Cell-Based NIPT for Commercialization as Clinical Studies Continue (GenomeWeb)

Oct 30, 2017 Julia Karow NEW YORK (GenomeWeb) – Arcedi Biotech of Denmark has been collaborating with six Danish hospitals to clinically validate its technology for isolating circulating fetal cells from maternal blood and analyzing their DNA for noninvasive prenatal diagnostics. Arcedi hopes to commercialize the technology in the near future through a large diagnostic […]

read more

On the road to replacing invasive testing with cell‐based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism

Objective: Trophoblastic fetal cells harvested from maternal blood have the capacity to be used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT). Potentially, this will result in increased resolution for detection of subchromosomal aberrations due to high quality DNA not intermixed with maternal DNA. We present 5 selected clinical cases from first […]

read more

12-10-17 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES PUBLICATION HIGHLIGHTING SUCCESS OF CUTTING-EDGE CELL-BASED NONINVASIVE PRENATAL TESTING TO DETECT ANEUPLOIDY AND SUBCHROMOSOMAL ABNORMALITIES IN FIRST TRIMESTER PREGNANCIES – Preliminary Results Identical to Invasive “Gold-Standard” Testing – Vejle, Denmark, October 12, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, […]

read more

A Noninvasive Future – Prenatal Genetic Testing Looks to Single-Cell Methods as the Next Frontier

ClinicalOmics By Helen Albert|August 2017 Prenatal genetic testing has advanced enormously over the last few decades. Amniocentesis and chorionic villus sampling (CVS) have been performed to diagnose fetal abnormalities for many years, but these tests are invasiveand not without problems. The risk for miscarriage is low (approximately 1 in 1000 for amniocentesis and 1 in 500 […]

read more

Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled

Biomark Med. 2017 Jun 15 Singh R, Hatt L, Ravn K, Vogel I, Petersen OB, Uldbjerg N, Schelde P For decades it has been common knowledge that some cells from the developing fetus make their way into maternal circulation, and that this process starts in the early weeks of first trimester. Naturally, when alternative technologies for prenatal diagnosis were being explored, the use of […]

read more

Arcedi Biotech aims to advance prenatal testing to whole genome, noninvasively

BioMed WorldTech By Katie Pfaff|July 11, 2017 Arcedi Biotech ApS provides noninvasive cell-based prenatal testing options beyond traditional methods, like amniocentesis. The Vejle, Denmark-based company’s technology isolates maternal and fetal cells for more comprehensive testing and rare cell detection in fetal samples. “This is going to be the first cell-based noninvasive prenatal test that is […]

read more

10-07-17 PRESS RELEASE

ARCEDI BIOTECH PUBLISHES ARTICLE HIGHLIGHTING ADVANCEMENTS AND POTENTIAL OF CELL-BASED NONINVASIVE PRENATAL TESTING TO DETERMINE PROBABILITY OF FETAL ABNORMALITIES – Company’s Technology Isolates Fetal Cells from Maternal Blood Samples Allowing for Whole Genome Amplification – Vejle, Denmark, July 10, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare cell detection for use in […]

read more

News and Notes from PNDx 2016 (Diagnostics World News)

By Benjamin Ross|December 9, 2016 The fourth annual Advances in Prenatal Molecular Diagnostics Conference took place last week in Cambridge, Massachusetts. The conference focused the bulk of its efforts on addressing two important, parallel issues: the science involved in cell-free vs. circulating fetal cells, and the angle of genetic counseling that impacts both the patient and […]

read more